GlaxoSmithKline says that it will begin regulatory submissions for its umeclidinium bromide (UMEC) and vilanterol (VI) dry powder inhaler for the treatment of COPD by the end of 2012. GSK is partnered with Theravance on this product, which will be delivered by the Ellipta inhaler.
The two companies also announced the completion of the Phase 3 clinical program. Results for four Phase 3 studies were reported earlier this year.
Read the GSK Theravance press release.
